Dr. Qu Zhican Takes Stage at 2025 China Pharmaceutical Innovation Summit and Delivers Keynote Speeches on RDC and ADC
Release time:
2025-12-01
From November 24 to 26, 2025, the 17th China Pharmaceutical Innovation Summit (CIPS) & Haidian Healthcare Full Industry Chain Innovation Summit was grandly held in Beijing. The event brought together numerous industry leaders, experts, scholars, and investors from institutions such as Sino Biopharmaceutical, BeiGene, and Fosun International. Centered around the theme of "Structural Inflection Point," participants jointly explored the pathways for high-quality development in China's pharmaceutical industry.
Dr. Qu Zhican, Chairperson of Nanolattix Group, attended the summit as a distinguished guest and delivered keynote speeches at two core forums: the "ADC Technology Innovation Forum" and the "Nuclear Power Leap · Future of Medicine: Innovative Nuclear Drug Forum." She systematically elaborated on Nanolattix's innovative strategies and core progress in cutting-edge drug development.
During the conference, based on industry development trends, Dr. Qu Zhican shared in-depth insights into Nanolattix's holistic R&D approach to advancing synergistic innovation in the fields of RDC and ADC. She highlighted Nanolattix's unique "ADC + RDC Dual-Track Innovation, Theranostic Integration" system. Guided by the core philosophy of "What is visible is treatable," this system provides an innovative paradigm for the future of precision medicine.
T320, a core ADC drug developed by Nanolattix leveraging its proprietary BioLattix technology platform, is currently undergoing Phase I/II clinical studies simultaneously in China, the United States, and Australia. The company's globally pioneering "ADC + RDC Shared Antibody" combination (T320-ADC and RT01-RDC), developed under the "Theranostic Integration" concept, has demonstrated significant clinical potential and technological synergy.
In a subsequent roundtable dialogue, Dr. Qu Zhican engaged in in-depth exchanges with multiple industry guests. Together, they explored the future landscape of pharmaceutical innovation and reached broad consensus on promoting industry-academia-research collaborative innovation and building a cooperative ecosystem. Nanolattix remains committed to an open and collaborative approach, willing to join hands with all stakeholders across the biopharmaceutical industry chain to jointly advance the high-quality development of pharmaceutical innovation in China and bring more cutting-edge scientific and technological achievements to benefit patients worldwide.
Tag:
recommend News
Share
